ATE366743T1 - Rekombinante nodavirus-zusammensetzungen und verfahren - Google Patents

Rekombinante nodavirus-zusammensetzungen und verfahren

Info

Publication number
ATE366743T1
ATE366743T1 AT98961962T AT98961962T ATE366743T1 AT E366743 T1 ATE366743 T1 AT E366743T1 AT 98961962 T AT98961962 T AT 98961962T AT 98961962 T AT98961962 T AT 98961962T AT E366743 T1 ATE366743 T1 AT E366743T1
Authority
AT
Austria
Prior art keywords
nodavirus
compositions
methods
recombinant
particles
Prior art date
Application number
AT98961962T
Other languages
English (en)
Inventor
Stephen Hall
Original Assignee
Pentamer Pharmaceuticals Inc
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentamer Pharmaceuticals Inc, Scripps Research Inst filed Critical Pentamer Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE366743T1 publication Critical patent/ATE366743T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/30011—Nodaviridae
    • C12N2770/30022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/882—Assembling of separate components, e.g. by attaching
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT98961962T 1997-12-08 1998-12-07 Rekombinante nodavirus-zusammensetzungen und verfahren ATE366743T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/986,659 US6171591B1 (en) 1997-12-08 1997-12-08 Recombinant nodavirus compositions and methods

Publications (1)

Publication Number Publication Date
ATE366743T1 true ATE366743T1 (de) 2007-08-15

Family

ID=25532635

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98961962T ATE366743T1 (de) 1997-12-08 1998-12-07 Rekombinante nodavirus-zusammensetzungen und verfahren

Country Status (14)

Country Link
US (1) US6171591B1 (de)
EP (1) EP1037917B1 (de)
JP (1) JP4503172B2 (de)
AT (1) ATE366743T1 (de)
AU (1) AU755201B2 (de)
BR (1) BR9813416A (de)
CA (1) CA2313704C (de)
CY (1) CY1106842T1 (de)
DE (1) DE69838073T2 (de)
DK (1) DK1037917T3 (de)
ES (1) ES2288769T3 (de)
IL (2) IL136634A0 (de)
PT (1) PT1037917E (de)
WO (1) WO1999029723A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69929232T2 (de) 1998-10-21 2006-08-31 The United States Government As Represented By The Department Of Health And Human Services Virusähnliche partikel zur induktion von autoantikörpern
EP1637166A3 (de) * 1998-10-21 2006-04-12 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Virusähnliche Partikel zur Induktion von Autoantikörpern
WO2001002551A2 (en) * 1999-06-30 2001-01-11 Evotec Oai Ag Virus like particles, preparation and use in screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7273708B2 (en) * 2001-07-02 2007-09-25 Bioincept, Llc Assays for preimplantation factor and preimplantation factor peptides
US8222211B2 (en) * 2001-07-02 2012-07-17 Bioincept, Llc Methods of administering PIF agonist peptides and uses thereof
DE60234375D1 (de) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
EP1318195A1 (de) * 2001-12-10 2003-06-11 CatchMabs B.V. Ein Struktur für die Präsentation erwünschter Peptidsequenzen
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
AU2004224761A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US7723290B2 (en) * 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
JP2005272340A (ja) * 2004-03-24 2005-10-06 Japan Science & Technology Agency ノダウイルスの感染予防法および治療法
BRPI0611336A2 (pt) 2005-06-01 2010-08-31 Dow Global Technologies Inc método para produzir uma partìcula multivalente semelhante a vìrus, partìcula multivalente semelhante a vìrus, método de aumentar a solubilidade de uma partìcula multivalente semelhante a vìrus e vacina
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
CA2636139A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
EP1835031A1 (de) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Verwendung eines rekombinanten modifizierten Vaccinia Ankara Virus (MVA) zur Behandlung der Typ-I Hypersensitivität in einem lebenden Tier einschließlich des Menschen
US8541559B2 (en) 2006-06-12 2013-09-24 Cytos Biotechnology Ag Process for producing aggregated oligonucleotides
US8586728B2 (en) 2006-12-12 2013-11-19 Cytos Biotechnology Ag Oligonucleotides containing high concentrations of guanine monomers
US7998487B2 (en) * 2007-02-16 2011-08-16 The Salk Institute For Biological Studies Antitoxin and vaccine platform based on nodavirus VLPs
CN101784655A (zh) * 2007-04-27 2010-07-21 菲尼克斯股份有限公司 可溶性重组二十面体病毒样颗粒的改良生成和体内装配
EP2217699A4 (de) * 2007-10-22 2012-11-28 Univ Rochester Respiratorisches-syncytial-virus-impfstoff auf der grundlage chimärer papillomavirus-ähnlicher partikel oder capsomeren
US9737585B2 (en) 2011-03-02 2017-08-22 Bioincept, Llc Compositions and methods for treatment of intracellular damage and bacterial infection
WO2013090409A1 (en) 2011-12-12 2013-06-20 The Children's Hospital Of Philadelphia Large commercial scale lentiviral vector production system and vectors produced thereby
WO2017039751A1 (en) 2015-08-28 2017-03-09 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
EP3184639B1 (de) * 2014-08-21 2019-06-12 Chung-Ang University Industry-Academy Cooperation Foundation Auf rdna-nts basiertes einsatzkassettenset mit mehreren genen und rekombinanter hefestamm von gras-qualität
EP3341006A4 (de) 2015-08-28 2019-03-13 BioIncept LLC Zusammensetzungen und verfahren zur behandlung von nervenschäden

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4873192A (en) * 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
EP0698666B1 (de) * 1994-06-21 2006-04-26 Sumitomo Electric Industries, Limited Modifiziertes Epimorphin
AT402898B (de) 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
US5869287A (en) * 1996-07-12 1999-02-09 Wisconsin Alumni Research Foundation Method of producing particles containing nucleic acid sequences in yeast

Also Published As

Publication number Publication date
PT1037917E (pt) 2007-09-19
WO1999029723A1 (en) 1999-06-17
JP2001525422A (ja) 2001-12-11
EP1037917B1 (de) 2007-07-11
CY1106842T1 (el) 2012-05-23
DE69838073T2 (de) 2008-03-20
CA2313704C (en) 2009-04-07
ES2288769T3 (es) 2008-01-16
AU1714699A (en) 1999-06-28
BR9813416A (pt) 2001-10-16
IL136634A (en) 2007-09-20
DE69838073D1 (de) 2007-08-23
AU755201B2 (en) 2002-12-05
JP4503172B2 (ja) 2010-07-14
CA2313704A1 (en) 1999-06-17
US6171591B1 (en) 2001-01-09
DK1037917T3 (da) 2007-10-08
IL136634A0 (en) 2001-06-14
EP1037917A4 (de) 2003-02-26
EP1037917A1 (de) 2000-09-27

Similar Documents

Publication Publication Date Title
ATE366743T1 (de) Rekombinante nodavirus-zusammensetzungen und verfahren
ATE327259T1 (de) Immunantwort gegen hpv antigene hervorgerufen von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einem expressionsvektor fähig zur expression dieser proteine
ATE279947T1 (de) Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
DE60033293D1 (de) Neue b7-4 moleküle und deren verwendungen
ATE500323T1 (de) Subtilisin-variante
ATE286067T1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
ATE419358T1 (de) Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins
DE3682893D1 (de) Charakteristische polypeptide und antikoerper vom papillomavirus, diagnostische verfahren und dieselben verwendende impfungen.
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
ATE378590T1 (de) Verfahren zum auffinden von peptiden zur verwendung in der immuntherapie
DE60144021D1 (de) Für zellzyklusproteine kodierende nukleinsäure und deren verwendung
MY110899A (en) Dengue virus
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
AP2368A (en) Novel expression vectors and uses thereof.
DK0625157T3 (da) Blodplade-GPIIIaP1A1- og -P1A2-epitoper og fremstilling og anvendelse deraf
ATE124420T1 (de) Impfstoffe und testsätze für haemophilus influenzae.
ATE424450T1 (de) Chimärische leere capside des ibdv (infectious bursal disease virus), gewinnungsverfahren und anwendungen
WO1992011370A3 (de) Von proteinen des hepatitis c-virus abgeleitete polypeptide und deren verwendung
DE60142356D1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
WO2001079473A3 (en) 21953, a human prolyl oligopeptidase family member and uses thereof
DE3782350D1 (de) Rekombinante parvovirus-ra-1-produkte und verfahren zu deren anwendung.
DE60018605D1 (de) Ing2, ein mit iaps assoziiertes zellzyklusprotein, sowie zusammensetzungen, verfahren und verwendungen
DK1328621T3 (da) 13245, en ny human proteinkinase af den myotoniske dystrofitype og anvendelser deraf